



UroSense™

UroSense™ redefines urologic diagnostics through a non-invasive, urine-based liquid biopsy that delivers precise early detection and monitoring of urologic conditions. Designed exclusively for urologists, it empowers superior patient care with actionable results.

An innovative Liquid Biopsy Technology

Key Benefits of UroSense™

Non-Invasive & Patient-Friendly: A simple urine sample replaces frequent invasive procedures like cystoscopy.

Enhanced Early Detection: Detects biomarkers at the earliest stages, including tumor burden as low as 0.5%, providing more sensitivity than traditional methods.

Monitoring & Risk Stratification: Tracks disease progression, evaluates treatment efficacy through dual DNA and RNA analysis, and supports personalized treatment plans.

Fast & Reliable Results: Maximizes sensitivity and turnaround time with unparalleled precision in molecular assessment.

Why Monitoring Tools Matter

Bladder cancer's high recurrence rates demand effective monitoring to detect recurrence early, assess treatment success, and manage risks. UroSense™ excels by offering:

- + **Early Recurrence Detection:** Identifies recurrence early for timely intervention.
- + **Treatment Effectiveness:** Evaluates therapy success with molecular precision, improving outcomes.
- + **Comfortable Surveillance:** Provides non-invasive options, reducing patient burden while advising quicker intervention when necessary.
- + **Lifelong Care:** Supports long-term monitoring for delayed recurrences, ensuring comprehensive care.

* **Results Within 24 Hours**



WHY UroSense™

**Non-Invasive
Early Detection
Patient Friendly
Same Day Results***

**Up to 70% of
Bladder Cancers
recur.**

